


## CCPA

Cat. No.:	HY-103185
CAS No.:	37739-05-2
Molecular Formula:	C <sub>15</sub> H <sub>20</sub> ClN <sub>5</sub> O <sub>4</sub>
Molecular Weight:	369.8
Target:	Nucleoside Antimetabolite/Analog
Pathway:	Cell Cycle/DNA Damage
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



## SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (270.42 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
			1 mM	2.7042 mL	13.5208 mL	27.0416 mL
			5 mM	0.5408 mL	2.7042 mL	5.4083 mL
			10 mM	0.2704 mL	1.3521 mL	2.7042 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.76 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.76 mM); Clear solution					

## BIOLOGICAL ACTIVITY

Description	CCPA (2-Chloro-N6-cyclopentyladenosine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc <sup>[1]</sup> .
-------------	--

## REFERENCES

- [1]. Man S, et al. Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 2021 Jun;26(6):1490-1500.
- [2]. Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA